Ulixertinib
- Generic Name
- Ulixertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2N4O2
- CAS Number
- 869886-67-9
- Unique Ingredient Identifier
- 16ZDH50O1U
- Background
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory LymphomaRefractory Multiple Myeloma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Radionuclide ImagingDrug: Ulixertinib
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT06400225
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Phase 2
Active, not recruiting
- Conditions
- Recurrent GliomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant Solid NeoplasmRecurrent NeuroblastomaRecurrent OsteosarcomaRefractory Malignant Germ Cell TumorRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaWilms Tumor
- Interventions
- Other: Pharmacokinetic StudyDrug: Ulixertinib
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT03698994
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmJuvenile XanthogranulomaLangerhans Cell HistiocytosisMalignant GliomaRecurrent Childhood RhabdomyosarcomaRecurrent Ewing SarcomaRecurrent OsteosarcomaRecurrent Primary Central Nervous System NeoplasmRefractory HepatoblastomaRefractory Medulloblastoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyProcedure: Mutation Carrier ScreeningDrug: Larotrectinib SulfateProcedure: Bone ScanOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: Selumetinib SulfateDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Radionuclide ImagingProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmBreast CarcinomaCervical CarcinomaLiver CarcinomaMalignant Uterine NeoplasmRecurrent Gastric CarcinomaRecurrent Head and Neck CarcinomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Rectal Carcinoma
- Interventions
- Drug: AfatinibDrug: BinimetinibDrug: AdavosertibDrug: CapivasertibDrug: Afatinib DimaleateProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: DabrafenibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibDrug: DefactinibDrug: SapanisertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: TaselisibDrug: UlixertinibDrug: Copanlisib HydrochlorideBiological: Trastuzumab EmtansineBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibDrug: Larotrectinib SulfateProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath